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Quantitative Shotgun Proteomics Unveils
Candidate Novel Esophageal Adenocarcinoma
(EAC)-specific Proteins*□S
J. Robert O’Neill‡§¶¶, Hui-Song Pak¶, Erola Pairo-Castineira!**, Vicki Save‡‡,
Simon Paterson-Brown§, Rudolf Nenutil§§, Borˇivoj Vojteˇsˇek§§, Ian Overton!**,
Alex Scherl¶, and Ted R. Hupp‡§§
Esophageal cancer is the eighth most common cancer
worldwide and the majority of patients have systemic
disease at presentation. Esophageal adenocarcinoma
(OAC), the predominant subtype in western countries, is
largely resistant to current chemotherapy regimens. Se-
lective markers are needed to enhance clinical staging
and to allow targeted therapies yet there are minimal
proteomic data on this cancer type. After histological re-
view, lysates from OAC and matched normal esophageal
and gastric samples from seven patients were subjected
to LC MS/MS after tandemmass tag labeling and OFFGEL
fractionation. Patient matched samples of OAC, normal
esophagus, normal stomach, lymph node metastases and
uninvolved lymph nodes were used from an additional 115
patients for verification of expression by immunohisto-
chemistry (IHC).
Over six thousand proteins were identified and quanti-
fied across samples. Quantitative reproducibility was
excellent between technical replicates and a moderate cor-
relation was seen across samples with the same histology.
The quantitative accuracy was verified across the dynamic
range for seven proteins by immunohistochemistry (IHC) on
the originating tissues. Multiple novel tumor-specific can-
didates are proposed and EPCAM was verified by IHC.
This shotgun proteomic study of OAC used a compara-
tive quantitative approach to reveal proteins highly ex-
pressed in specific tissue types. Novel tumor-specific pro-
teins are proposed and EPCAM was demonstrated to be
specifically overexpressed in primary tumors and lymph node
metastases compared with surrounding normal tissues. This
candidate and others proposed in this study could be devel-
oped as tumor-specific targets for novel clinical staging and
therapeutic approaches. Molecular & Cellular Proteomics
16: 10.1074/mcp.M116.065078, 1138–1150, 2017.
Esophageal cancer is the sixth leading cause of cancer
death worldwide (1) and esophageal adenocarcinoma (EAC)1
has become the predominant histological subtype in western
countries (2, 3). In the UK, 95% of patients diagnosed with
EAC will die from metastatic disease and the majority are
resistant, at presentation, to current platinum-based chemo-
therapy regimens (4–6).
EAC is frequently associated with both lymphatic and dis-
tant metastases yet current staging modalities including com-
puted tomography (CT), positron emission tomography (PET)
and endoscopic ultrasound (EUS) are limited in both sensitiv-
ity and specificity (5). Surgical resection only benefits patients
with localized disease and carries a 40% risk of major mor-
bidity and 2–3% risk of perioperative mortality (7, 8). The
development of accurate noninvasive imaging markers of
EAC would enhance clinical staging by allowing the specific
detection of locoregional and distant metastases, enabling
treatment stratification (9).
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The normal squamous epithelium-lined esophagus is vul-
nerable to toxic insult from the esophageal lumen. Indeed,
chronic reflux of gastric acid and bile is thought to underlie the
development of columnar metaplasia, “Barrett’s esophagus”,
the precursor lesion of EAC (10). Although the exact molecular
mechanisms of Barrett’s development and esophageal carci-
nogenesis remain obscure, the detection and treatment of
EAC at an early stage offers the prospect of long term cure
with over 80% of patients undergoing surgery for stage I
esophageal cancer surviving 5 years (11).
Intriguingly many of the genetic mutations present in EAC
have also been demonstrated in nondysplastic Barrett’s epi-
thelium raising the possibility that a transcriptional change
such as splicing or RNA-editing, or a post-translational mod-
ification is responsible for transformation (12). If such a bio-
marker could be identified this would offer the possibility of
earlier diagnosis and more effective treatment.
Characterizing the proteomic changes associated with
EAC may also allow novel therapies to be designed. Tumor-
specific proteins have been exploited as immunotherapeutic
targets in other cancer types by engendering a host response
to the cancer (13), in some cases leading to durable re-
sponses (14).
To date, no specific markers of EAC have been identified.
To identify candidate proteins de novo, expression must be
measured using untargeted proteomic methods.
Quantitative proteomic methods have now been applied
across many cancer tissues. Most previous proteomic studies
in EAC, however, have only identified a small number of
dysregulated proteins limiting the comparisons that can be
made between studies or with other cancers (summarized in
Table I). Only one of these previous studies employed a
quantitative shotgun proteomic strategy. The authors com-
pared pooled biopsies of EAC, normal esophagus, gastric
adenocarcinoma and normal gastric tissue and identified 972
proteins. Although no EAC-specific protein was identified,
neutrophil defensin 1, an antimicrobial peptide found in neu-
trophil granules, was overexpressed in both cancer types
relative to normal tissue (15). This may reflect the inflamma-
tory environment associated with these cancers.
The comparisons between EAC and normal squamous
epithelium in published work reveals many dysregulated
proteins, some of which represent proteins associated with
glandular differentiation and some associated with carcino-
genesis. Glandular-associated proteins may be expressed in
gastric and intestinal epithelium and may not represent trac-
table targets for therapy as toxicity because of intestinal ep-
ithelial damage would be expected. It is possible that in-
cluding columnar epithelium-lined gastric tissue along with
squamous and EAC tissue may enable the discrimination of
proteins that reflect glandular differentiation from those driv-
ing carcinogenesis.
Multitissue proteomic profiling has been applied across
mouse tissues with relative quantitation using a super-SILAC
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approach (16). In this study, snap-frozen biopsies from 28
tissue types were subjected to shotgun proteomics with a
spike-in, heavy-labeled mixture of all tissues obtained from
the SILAC mouse. By comparing the relative expression of
proteins across tissues, tissue-specific expression could be
highlighted. The esophagus was not included in this profiling
effort although gastrointestinal tissues with columnar epithelia
showed similar expression patterns (16). This comparative
approach has also been employed in a large proteomic study
of 30 human tissues by label-free quantification and again
tissue-specific expression patterns identified (17).
This biomarker discovery study therefore used a quantita-
tive shotgun proteomic strategy to evaluate protein expres-
sion in EAC and adjacent matched normal squamous and
gastric tissues from seven patients. By quantifying the relative
expression between EAC and normal esophagus and EAC
and normal stomach, proteins aberrantly expressed in EAC
were identified. The accuracy of this approach was confirmed
by immunohistochemistry for multiple candidates and a po-
tential tumor biomarker verified in a cohort of 115 patients
with resected EAC and matched normal and metastatic
tissues.
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—Fresh frozen biop-
sies representing macroscopically normal esophagus, normal stom-
ach and esophageal adenocarcinoma tissue were prospectively col-
lected from resection specimens from seven patients undergoing
neoadjuvant chemotherapy and attempted curative surgery for locally
advanced esophageal and esophagogastric junctional cancer at the
Royal Infirmary of Edinburgh between 2010 and 2012. Local institu-
tional ethical and research and development approvals were in place
(REC references 06/S1101/16 and 10/S1402/33) (R&D ID 2006/W/PA/
01). All patients gave informed consent and participants and their
donated samples were de-identified at the time of recruitment. Pa-
tients were selected for relative clinical homogeneity with respect to
known prognostic variables including lymphatic metastasis and tu-
mor differentiation (18). The clinical characteristics of the cohort are
presented in Table II.
At the commencement of this study, no shotgun proteomic data
were available for esophageal adenocarcinoma tissue to inform a
power calculation for sample size determination. The sample number
was therefore based on previous esophageal discovery-phase pro-
teomic studies or studies in similar tissue types (19–22), and the
availability of high quality clinical material.
Because of the risk of false-positives because of the small sample
size, proposed tumor-specific proteins identified by mass spectrom-
etry were additionally verified by immunohistochemistry (IHC) using
cores from archival tumors and matched normal and metastatic tis-
sues from an independent cohort of 115 patients with esophageal or
EGJ adenocarcinoma (clinical characteristics in supplemental Table
S1).
Sample Processing—The sample processing workflow is summa-
rized in Fig. 1. Fresh tissue biopsies were snap frozen within 30 min
of tumor extirpation and maintained in liquid nitrogen or on dry ice
until lysis. Frozen sections from each biopsy were reviewed by a
consultant histopathologist to confirm the histological diagnosis and,
for tumor biopsies, a minimum of 50% tumor cellularity.
The published Filter-Aided Sample Preparation (FASP) method was
adapted for protein extraction and tryptic digestion from esophago-
gastric tissue (23).
Biopsies between 30 mg and 60 mg in weight were maintained on
dry ice until rapid disruption at room temperature (RT) in low-binding
micro-centrifuge tubes containing 1 mm ceramic beads (Matrix D, MP
TABLE II
Clinical characteristics of patients donating tissue for proteomic analysis
Patient (Pt)
Pt44 Pt46 Pt48 Pt51 Pt53 Pt60 Pt61
Gender Male Male Male Male Female Male Male
Age 59 67 65 41 52 60 58
Histology ACC ACC ACC ACC ACC ACC ACC
Location EGJ Type II Eso Lower EGJ Type II EGJ Type I Eso Lower Eso Lower Eso Lower
Neoadjuvant therapy 2xCF 2xCF 2xCF 2xCF 2xCF 2xCF 2xCF
Surgery ILE ILE ILE ILE ILE ILE ILE
Tumor Diameter 38 mm 70 mm 40 mm 50 mm 83 mm 52 mm 35 mm
PRM and DRM !1 mm !1 mm !1 mm !1 mm !1 mm !1 mm !1 mm
Distance to CRM 4.2 mm 0.0 mm 0.0 mm 0.3 mm 3.0 mm 1.0 mm 1.0 mm
Resection R0 R1 R1 R1 R0 R0 R0
Differentiation Moderate Poor Poor Poor Poor Poor Poor
LVI Y Y Y Y N Y Y
Venous Invasion N N N Y N N N
PNI N Y Y Y N Y Y
T stage ypT2 ypT4a ypT3 ypT3 ypT2 ypT3 ypT3
N Stage ypN1 ypN3 ypN3 ypN3 ypN1 ypN3 ypN2
Positive nodes 2 8 16 7 1 7 3
Nodes resected 27 18 28 28 23 21 37
AJCC Stage IIB IIIC IIIC IIIC IIB IIIC IIIB
Mandard TRG V V IV V IV V V
Alive at analysis No No No No Yes No Yes
Overall survival 48.1 months 15.3 months 10.9 months 24.1 months 47.6 months (censored) 17.8 months 49.0 months (censored)
Recurrence-free survival 34.8 months 12.6 months 10.1 months 10.9 months 47.6 months (censored) 8.1 months 49.0 months (censored)
Abbreviations: ACC, Adenocarcinoma, 2xCF-2 cycles of Cisplatin and 5-Fluorouracil; ILE, Ivor-Lewis Esophagectomy; mm–millimetre,
AJCC, American Joint Committee on Cancer; EGJ, Esophagogastric Junctional Tumour; PRM, Proximal resection margin; DRM, Distal
resection margin; CRM, Circumferential resection margin; LVI, Lymphovascular invasion; PNI, perineural invasion, Y-Yes, N-No; CT, Computed
Tomography, Mandard; TRG, Tumour Regression Grade; Eso, Esophagus.
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Bio, Santa Ana, CA) by rapid shaking in a bench-top homogenizer
(FastPrep-24, MP Bio) for 40 s at 6ms"1. Homogenates were dis-
solved in FASP lysis buffer (4% w/v SDS, 100 mM Tris/HCl, 100 mM
DTT, pH 7.6), mixed for 20 min at RT and sonicated at maximum
amplitude, for 30 s, on ice, using a needle sonicator (Bioruptor,
Diagenode, Lie`ge, Belgium). Sonicated lysates were heated for 5 min
at 95 °C and clarified by centrifugation at 14,000g for 5 min at 20pC
before buffer-exchange as per the published FASP protocol (23).
Trypsinization was performed off-column, overnight at 37 °C at a ratio
of 100:1 (lysate protein mass : trypsin mass) using sequencing grade
modified trypsin (Promega, Madison, WI) as per manufacturer’s
instructions. Protein concentration was determined using a modi-
fied Lowry procedure as per the manufacturer’s recommendations
(RC-DC, Bio-Rad, Hercules, CA).
Isobaric labeling and Fractionation of Tryptic peptides—Tryptic
peptides from each tissue sample were independently labeled with
one of the 6 Tandem Mass Tag (TMT) reagents (Thermo Scientific,
San Jose, CA) in technical duplicate per manufacturer’s instructions
(Fig. 1). Labeled peptides from a single patient (6 reporter ions) were
pooled, desalted on a Macro SpinColumn C18 (Harvard Apparatus,
Holliston, MA) and separated into 24 fraction by OFFGEL electropho-
resis as previously described (24).
Liquid Chromatography—Dried, desalted peptide fractions were
reconstituted in 5% (v/v) acetonitrile, 0.1% (v/v) Formic Acid (FA) in
dH2O and #0.5 !g loaded onto a homemade, 100 !m internal diam-
eter, 20 mm long trapping column packed with 200 Å, 5 !m Magic
C18 AQ (Michrom, Auburn, CA). Trapped peptides were eluted into a
75 !m internal diameter, 150 mm long analytical column packed with
100 Å, 3 !m Magic C18 AQ (Microcom).
For ultraperformance liquid chromatography (UPLC), peptides
were separated using a variable solvent gradient created by a com-
bination of 0.1% (v/v) FA in dH2O (solvent A) and 0.1% (v/v) FA in
acetonitrile (solvent B). The gradient was run as follows: 0–1 mins,
95% (A) and 5% (B), 1–56 mins, 65% (A) and 35% (B), 66–76 mins,
20% (A) and 80% (B) using a flow rate of 220 nL/min.
Mass Spectrometry—Peptides were analyzed in positive ion mode
after electrospray ionisation on an LTQ-Orbitrap Velos mass spec-
trometer (Thermo Scientific, San Jose, CA). For MS survey scans, the
Orbitrap (OT) resolution was set to 60,000 and the ion population was
set to 5 $ 105 with an m/z window from 400 to 2000. A maximum of
three precursor ions with the greatest peak intensities were selected
for both collision-induced dissociation (CID) and high-energy C-trap
dissociation (HCD) in the LTQ with analysis in the OT. For fragment
ion analysis in the LTQ, the ion population was set to 7 $ 103
(isolation width of 2 m/z) whereas for detection in the OT, the ion
population was set to 2 $ 105 (isolation width of 2.5 m/z), with
resolution of 7500, first mass at m/z % 100, and maximum injection
time of 750 ms. The normalized collision energies were set to 35% for
CID and 60% for HCD.
Protein Identification—Protein identifications were made using the
Easyprot platform (v2.3 build 720, Swiss Institute of Bioinformatics)
(25). Data manipulation was performed using Excel (Version 14.0.
6129.5000, Microsoft Office Professional 2010), R (version 2.
15.1, General Public License), and custom scripts written in Perl
(version 5.18.0, General Public License).
Thermo RAW files were converted to peak lists using ReAdW
(version 4.3.1, ThermoFinnigan) and CID and HCD spectra were
merged for simultaneous identification and quantification as previ-
ously described (26). Peaklist files were searched against the Uniprot
human reference proteome (release 09/01/2013, containing 87,613
entries) using Phenyx® (version 2.6.1, GeneBio) (27) with a precursor
ion tolerance of 10 parts per million and a fragment ion tolerance of
0.6 Da. Variable peptide modifications included TMT-modified N ter-
mini and lysines (additional 229.1629 Da) and oxidized methionines,
with carbamidomethylation of cysteines set as a fixed modification.
Trypsin was selected as the digestion enzyme, with one potential
missed cleavage and a minimum of a single-tryptic terminus, a pep-
tide length of 6 amino acids and a z-score of 4 were required.
All data sets were searched separately, once using a forward and
once using a reversed protein database. The peptide false discovery
rate was set to 1%. A single unique peptide was accepted for pro-
tein identification. Identified peptide sequences, scores, precursor
m/z, corresponding proteins, protein coverage and raw data files
have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner re-
pository (28) with the dataset identifier PXD004962.
Protein Quantitation—For relative protein quantitation, the TMT
reporter ion intensities were extracted for each peptide. An isotopic
purity correction was performed within Easyprot for each reporter
based on the isotopic distribution of the sixplex-TMT reporters pro-
vided by the manufacturer.
The ratios of peptide expression between EAC and normal esoph-
agus (TvE) and EAC and normal gastric epithelium (TvG) were calcu-
lated for each peptide as the ratio of 126/128 reporter ion intensities
and 126/130 reporter intensities respectively. This was repeated for
127/129 (TvO) and 127/131 (TvG) reporter ions as a technical repli-
cate. The geometric mean peptide TvE and TvG ratios were calcu-
lated for each protein to derive an estimate of the relative protein
expression between patient-matched tissue types, and limiting the
skew introduced by outlier ratios (29). Because of the ambiguity from
potentially shared peptides, all protein isoforms were grouped under
the parent protein identifier (Uniprot accession). The variance of each
ratio and the number of peptides contributing to the mean were used
for subsequent significance calculations.
Deriving a Mean Expression Ratio across Replicates—A mean ex-
pression value was derived across pooled technical and biological
replicates by a meta-analysis approach using a fixed-effect model
(30). The inverse of the variance in peptide reporter ratios was used to
weight the contribution of protein expression from a replicate to the
127 128 129 130 131
Pool
ACC
 nanoLC-MS/MS (LTQ Orbitrap)
24 Fractions
126
Phenyx/Easyprot 
Eso Sto Lysis
Digestion
TMT Labelling
OFFGEL ELECTROPHORESIS
For Each Patient (n=7)
Fractionation
LC MS/MS
Protein 
Identifications
Tissue Collection
Verify Histology
FIG. 1. Summary experimental workflow. Tryptic peptides from
histologically-verified, fresh frozen tissue biopsies were labeled with
TMT reporters prior to OFFGEL electrophoresis and tandem mass
spectrometry. Abbreviations: ACC, Adenocarcinoma biopsies; Eso-
normal squamous esophageal biopsies; Sto-normal gastric biopsies.
TMT, Tandem Mass Tags; LC; Liquid Chromatography; MS/MS, Tan-
dem Mass Spectrometry.
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mean. In this manner, replicates with many peptides detected with
similar relative tissue expression (low variance) for a protein contrib-
ute a greater proportion to the mean expression value (see supple-
mentary Methods). The unweighted arithmetic mean and variance of
the ratios across experiments was calculated for proteins identified by
a single unique peptide in multiple replicates. The log2-transformed
protein expression ratios (TvE and TvG) were median normalized to
account for systematic errors during TMT labeling such as minor
variations in protein loading.
Statistical Tests—The intertissue ratios (TvE and TvG) were com-
pared with technical replicates (TvT, EvE and TvT, GvG) using Welch’s
modified t test (31) as the variances between them differed signifi-
cantly (32); Fligner-Killeen test p & 10"10, supplemental Fig. S1.
Welch’s t test was used to test the hypothesis that the relative protein
expression between different tissues was not different from relative
protein expression between technical replicates with “n” defined as
the number of peptides contributing to the mean ratio (see supple-
mentary Methods) (33). All p values were corrected using the Benja-
mini-Yekuteili method to control for multiple hypothesis testing (34).
Significance was defined as a false discovery rate (FDR)-corrected
p & 0.05 and p values were two-tailed. Relative quantitation and
significance are provided for all identified proteins (uploaded supple-
mentary file; All_quantitation.xlsx).
Immunohistochemistry—For verification of relative protein expres-
sion, 4 !m sections were cut from formalin-fixed, paraffin-embedded
(FFPE) blocks derived from the same resection specimens used to
collect the fresh tissue for this study and representing normal esoph-
agus, normal stomach and EAC. Sections were subjected to immu-
nohistochemical staining using standard techniques as previously
described (35). Staining conditions were optimized for each antibody,
included a no primary antibody control for each protein and are
detailed in supplemental Table S2.
Tissue Microarray—After institutional approval (R&D ID 2006/W/
PA/01), FFPE blocks comprising normal esophagus, normal stomach,
EAC, normal lymph nodes and, if present, lymph node metastasis
were identified for an independent cohort of 115 patients undergoing
esophageal resection for EAC between 1994 and 2005 (supplemental
Table S1). Representative cores (0.6 mm) were transferred to a sep-
arate paraffin block as a tissue microarray (TMA). TMA sections (4
!m) were stained as previously and scored using a modified Allred
method (36) by an expert histopathologist. Intensity was graded 0–3
(0 % nil, 1 % weak, 2 % moderate, 3 % strong) and frequency was
graded 0–4 (0 % 0%, 1 % 1–10%, 2 % 10 % 50%, 3 % 50–80%, 4 %
80–100%). The sum of intensity ' frequency was calculated for each
scorable core. Not all cores could be scored because of loss of
material during IHC or lack of the appropriate tissue type in the core.
Western Blotting and RNA Interference—Lysates from each of the
esophageal cell types growing under basal conditions were resolved
by SDS-PAGE (20 !g protein per lane, 12% SDS gel) as previously
described (37). Western blots were probed with primary antibodies
directed against ARHGDIB (ab88317, Abcam, Cambridge, UK, 1/500
overnight at 4 °C) or "-Actin (AC-15, Sigma, Dorset, UK, 1/5000, 2 h
at RT) followed by secondary incubation with rabbit anti-mouse or
goat anti-rabbit antibodies conjugated to either the IRDye™ 680RD or
IRDye™ 800CW ((Li-Cor Biosciences, Lincoln, NE, 1/2000, 2 h at RT
protected from light). Blots were imaged using the Odyssey SA sys-
tem (Li-Cor Biosciences) as per manufacturer’s recommendations.
For siRNA experiments, OE33 cells were transfected with vector,
nontargeting scrambled sequence siRNA (siGENOME, Non-Targeting
siRNA#3, Dharmacon, Lafayette, CO) or siRNA to ARHGDIB (siG-
ENOME, SMARTPool, Dharmacon) as previously described (37). Cells
were harvested 72 h after transfection and lysates resolved by West-
ern blotting as previously.
RESULTS
A total of 6349 proteins were identified and quantified
across all samples corresponding to 4772 unique Entrez
GeneIDs with 744 proteins quantified in both replicates from
all seven samples. The protein identifications per patient are
shown in Table III.
Reproducibility of Quantitation—The reproducibility of
quantification of protein expression was assessed by com-
paring technical replicates. Expression levels were highly cor-
related between technical replicates from the same patient’s
tissues (Fig. 2A, 2B, median Pearson correlation coefficient
(PCC) % 0.9811, p & 0.001). There was also a reassuringly
good correlation between different patients (biological repli-
cates) when TvE ratios were considered (Fig. 2C, median
PCC % 0.555, p & 0.001) demonstrating concordance of the
protein expression from histologically similar tissues within a
relatively clinically homogeneous patient cohort. As expected,
there was no significant correlation between TvE and TvG
ratios across patients (Fig. 2C, median PCC % 0.0115, p !
0.05) underscoring the diversity in protein expression of the
tissues studied.
A Map of Protein Expression across Esophagogastric Tis-
sues—Protein expression was quantified by the ratio of TMT
reporter ion intensities. Ratios were not, however, calculable
for proteins exclusively expressed in one tissue and these
proteins may have been excluded from our analysis despite
their biological importance. Several peptides were manually
identified with no reporter ion expression from one or two
tissue types. In the context of other unique peptides identified
from the same protein, however, no proteins with entirely
tissue-specific expression could be identified in this study.
For the 4181 proteins identified by more than one peptide in
more than one replicate, and the 2154 proteins identified by
more than one peptide in a single replicate or a single peptide
in more than one replicate a mean expression value and
variance were derived (uploaded supplementary file; All_
quantitation.xlsx). Those 14 proteins identified by a single
peptide and only in a single replicate were considered low
confidence identifications and were excluded from further
analysis. The expression ratios for the 3082 proteins signifi-
cantly dysregulated between tissues (FDR-corrected p& 0.05
for either TvG or TvE ratios) were used to produce a two-
TABLE III
Protein identifications by patient
Patient
Total proteins (1% peptide FDR,
1 unique peptide per protein)
Unique to patient
Pt44 2901 368
Pt46 2534 256
Pt48 3309 550
Pt51 3327 503
Pt53 2904 280
Pt60 2369 220
Pt61 2828 264
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dimensional protein expression map with vectors of TvG ex-
pression on the x axis and TvE on the y axis (Fig. 3).
Proteins overexpressed in EAC would be expected to have
both high TvE and TvG ratios and therefore be identified in the
upper right quadrant of the protein expression plot, discrete
from other nonspecifically expressed proteins. It was pro-
posed that other proteins with tissue-specific expression pat-
terns would also be closely associated on the plot. To test this
hypothesis, proteins with an established expression pattern
were considered. Gastric Intrinsic Factor (GIF) and Mucin 5AC
are known to be specifically highly expressed in gastric epi-
thelium (38, 39). Reassuringly, both proteins were closely
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FIG. 2. Correlation of technical replicates. A, Median-normalized log2 ratios are displayed for two technical replicates of samples from
patient 44. TvE % log2 ratio of expression between EAC and normal esophagus. TvG % log2 ratio of expression between EAC and normal
gastric tissue. B, Box and whisker plot summarizing the median (line within the box), 25th and 75th percentiles (box limits) and 5th and 95th
percentiles (whiskers) for the Pearson’s correlation coefficients (PCC) for technical replicates across all experiments (n % 14). C, Heatmap
representation of PCC between technical replicates across all experiments. Unsupervised hierarchical clustering was performed using an
agglomerative complete linkage method to generate the similarity dendrogram (left).
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associated on the protein expression map and demonstrated
similar expression in EAC and normal esophageal tissue but
high expression in gastric epithelium (Fig. 3). Similarly, Kera-
tins 4, 5, and 14 are known to be highly expressed in esoph-
ageal squamous epithelium (40, 41) and were all clustered
together. It was possible that the tissue expression pattern of
other proteins could be inferred from their location on this
map.
To test this, a further two proteins predicted to be upregu-
lated in squamous tissue (heat shock protein family B (small)
member 1; HSPB1 and transglutaminase 3; TGM3), two pro-
teins upregulated in tumor but also generally expressed (SAM
and HD domain containing deoxynucleoside triphosphate
triphosphohydrolase 1; SAMHD1 and Rho GDP dissociation
inhibitor beta; ARHGDIB), two proteins upregulated in both
tumor and gastric tissue (anterior gradient 2, protein disul-
fide isomerase family member; AGR2 and heat shock pro-
tein family A (Hsp70) member 5; HSPA5) and one protein
predicted to be specifically highly expressed in tumor (epi-
thelial cell adhesion molecule; EPCAM) (supplemental Table
S3) were selected for verification by immunohistochemistry
(IHC).
Verification of Protein-expression Differences Across EAC
and Patient-matched Normal Tissues—Sections from the
FFPE tissue blocks from the original resection specimens
used to derive the fresh tissue samples for proteomic analysis
were subjected to IHC (Fig. 4). All five of the proteins pre-
dicted to be upregulated in EAC compared with normal
esophagus (SAMHD1, ARHGDIB, AGR2, HSPA5, EPCAM)
showed higher expression in the tumor sections compared
with squamous epithelium. Similarly, the proteins predicted to
be expressed preferentially in squamous epithelium; HSPB1
and TGM3, showed the highest expression in normal squa-
mous esophageal tissue (supplemental Table S3).
Although false positive homogeneous cytoplasmic staining
was observed in all or scattered basal crypt epithelial cells in
most gastric tissue sections (Fig. 4; No primary antibody) (42),
both HSPA5 and AGR2 demonstrated true gastric epithelial
staining as expected and were overexpressed in EAC com-
pared with squamous epithelium.
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FIG. 3. Distribution of Significantly Dysregulated Proteins. Significance was defined as an FDR-corrected p & 0.05 for the comparison
of TvE and the mean of TvT and EvE ratios or for the comparison of TvG and the mean of TvT and GvG ratios. Each point on this figure
represents a single protein that is significantly dysregulated in at least one tissue type. Proteins have been plotted according to their log2
expression ratios and points sized per the frequency of observation by MS across pooled biological and technical replicates (range 1–14).
Selected proteins, labeled by their official gene names, are highlighted in green for proteins known to be specifically expressed in gastric tissue,
purple for proteins known to be expressed in squamous tissue and red for proteins selected for further validation by IHC.
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SAMHD1 showed more widespread nuclear expression
across tissues but was mildly upregulated in EAC cells, as
predicted. In contrast, EPCAM was very highly expressed in
tumor cells with only moderate staining in basal epithelial
squamous cells and gastric epithelial cells. Although overall
expression of ARHGDIB was indeed higher in EAC compared
with normal squamous and gastric tissue, this staining was
observed in stromal cells, most likely lymphocytes, rather than
epithelial-derived tumor cells.
These findings support the accuracy of the quantitative
proteomic approach for each of the seven candidates se-
lected. As expected from the proteomic data, EPCAM dem-
onstrated the greatest specificity for tumor cells.
To determine the specificity of EPCAM for EAC cells com-
pared with surrounding normal tissues, protein expression
was determined by IHC using a tissue microarray consisting;
normal gastric tissue, normal squamous tissue, uninvolved
lymph nodes, involved lymph nodes and primary tumor sam-
ples from resection specimens from 115 patients whom had
undergone surgical resection for EAC (Fig. 5). EPCAM was
expressed at low levels in basal squamous epithelial cells
and low to moderate levels in gastric epithelium. In contrast
EPCAM was highly expressed in EAC and was expressed at
higher levels than the median normal gastric or normal esoph-
ageal epithelial expression in 98% of tumors. This high spec-
ificity was demonstrated in metastatic lesions as well as pri-
mary tumors with no EPCAM expression detectable in normal
lymph nodes but high expression in 93% of lymph node
metastases.
This proteomic strategy has therefore demonstrated the
ability to detect relatively specific markers of EAC. Those
proteins predicted to be highly expressed in EAC compared
with surrounding normal tissues, including several novel
candidate therapeutic targets, are presented in more detail
in Fig. 6.
DISCUSSION
There is a need to identify selective markers of esophageal
adenocarcinoma for early diagnosis, to enhance clinical stag-
ing and direct novel therapies. This shotgun proteomic study
compared protein expression from matched esophageal ad-
enocarcinoma, normal esophagus and normal gastric sam-
ples from seven patients and provides quantitative data on
protein expression for over 6000 proteins across these tis-
sues. A comparative analysis approach was employed to select
tumor-specific proteins and this method was verified to be
accurate by IHC. Multiple novel tumor-specific proteins are
proposed and EPCAM was demonstrated to be specifically
overexpressed in primary tumors and lymph node metastases.
Normal Squamous Normal Gastric EAC Normal Squamous Normal Gastric EAC
ARHGDIB
SAMHD1
AGR2
HSPA5
TGM3
HSPB1
EPCAM
No Primary
Antibody
FIG. 4. IHC staining pattern for selected proteins. Representative images are provided highlighting the staining pattern from EAC and
matched normal tissues from the original resection specimens used to derive the fresh frozen biopsies.
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Incomplete proteome coverage remains a significant limi-
tation of all proteomic studies, however, and only 744 proteins
(12%) were detected in all technical replicates across the
seven patients’ tissues. Despite this intrinsic limitation of pro-
teomic studies, the technical reproducibility of protein quan-
titation was very high and a strategy was developed to identify
significantly dysregulated proteins.
The combination of TvE and TvG ratios for each quantified
protein allowed the generation of a 2D expression map. The
relative quantitative accuracy of this approach was confirmed
first by evaluation of proteins with a well validated expression
profile (GIF, Muc5AC, Keratin 4,5,14) and then subsequently
by IHC for 7 further proteins with varied expression profiles
(ARHGDIB, SAMHD1, AGR2, HSPA5, EPCAM, TGM3, HSPB1).
In each case the observed staining pattern mirrored the ex-
pected expression from the proteomic data (supplemental
Table S3). This provides confidence in the predicted expres-
sion for proteins with an unknown pattern.
Both TGM3 and HSPB1 were found to be expressed at high
levels in squamous epithelium compared with EAC, as ex-
pected from our proteomic data and as reported in previous
work (43). In contrast, AGR2 was found to be expressed in
gastric epithelium and EAC with no expression observed in
squamous epithelia. Similarly, HSPA5 was found to be ex-
pressed in both EAC and gastric epithelium. These findings
agree with previous reports (44–48). HSPA5 is thought to play
a key role in the regulation of the unfolded-protein response
and this expression pattern may reflect an increased protein
chaperone demand in secretory cells (48, 49). Indeed, AGR2
has a function in protein homeostasis and secretion (50).
SAMHD1 exhibited nuclear expression in both epithelial
and nonepithelial cells with the highest expression in EAC. It
has a reported role in restricting HIV replication and modulat-
ing the immune response in T cells (51) but there is limited
data for its role in cancer and this would be worthy of further
study.
ARHGDIB was overexpressed in EAC sections compared
with normal squamous and normal gastric tissue. The ARHGDIB
positive cells appeared, however, to be lymphocytes rather
than epithelial-derived tumor cells. This expression pattern
has been observed for ARHGDIB with a different antibody (47)
and a multitissue study suggested expression was restricted
to hematopoietic cells (52).
Divergent roles for ARHGDIB have subsequently been pro-
posed in the literature with some evidence for a role in the
suppression of metastasis in bladder cancer (53) and in con-
trast a proinvasive role in gastric cancer (54). One previous
proteomic study reported ARHGDIB overexpression in EAC
compared with Barrett’s epithelium at both the mRNA and
protein level (22). In contrast to our study, the previous work
presented cytoplasmic and membrane staining in epithelial
cells with minimal stromal positivity in EAC sections. The
specificity of the rabbit anti-ARHGDIB antibody used in that
study was not demonstrated in the manuscript. In contrast the
antibody in this study identifies a protein of the predicted
mass (48 kDA) in a panel of esophageal cell lines by Western
blotting and is specific for that protein as confirmed by siRNA
(supplemental Fig. S2). The variable expression of ARHGDIB
noted in the panel of esophageal cell lines may reflect con-
text-dependent regulation. Staining across a larger number of
esophageal tumors could establish greater confidence over
the cell-specific expression profile.
The cancer antigen EPCAM was predicted to be highly
expressed in EAC cells compared with surrounding normal
tissues and this was indeed observed. This has previously
been demonstrated for several cancer types, including esoph-
ageal (55, 56). EPCAM is a cell adhesion molecule that is
highly expressed on the cell membrane and may possess a
signaling role through the regulation of cell proliferation via a
cleaved intracellular domain (57). Because of its high speci-
ficity for malignancy, EPCAM-based assays have been devel-
oped to detect circulating tumor cells although these are less
sensitive for mesenchymal tumors (58).
The expression of EPCAM was examined in detail by IHC in
an independent cohort of 115 esophageal adenocarcinomas
with matched normal and metastatic tissues. EPCAM was
highly expressed in the clear majority of EACs with higher EP-
CAM histoscores observed in 85/87 EACs than the median
gastric or esophageal scores. EPCAM was also highly specifi-
cally expressed in lymph node metastases compared with sur-
rounding normal lymph nodes raising the possibility that it could
exploited to enhance clinical staging using novel techniques (59).
These data agree with previous work demonstrating over-
expression of EPCAM in EAC compared with surrounding
normal tissues (56). A further study identified disseminated
tumor cells from bone marrow and lymph nodes in patients
with esophageal cancer and, although the primary tumors
predominantly expressed high levels of EPCAM, EPCAM ex-
pression was only observed in 37% of disseminated tumor
cells from bone marrow aspirates (60). A reduction in EPCAM
expression by RNA interference increased migration in vitro
and the authors proposed that EPCAM expression reduced
during the process of invasion as cells adopted a more mes-
enchymal phenotype. This may have clinical implications if
anti-EPCAM therapies are to be considered.
Samples were obtained from six men and one woman
(Table II) reflecting the 4-fold greater prevalence of EAC in
men (18). Although this bias could limit the applicability of this
study to women with EAC, no differences were noted in the
expression patterns of EPCAM across tissue types from men
(n % 97) and women (n % 18) in the TMA.
EAC exhibits a high frequency of DNA mutation and mutant
proteins are highly likely to be tumor specific (12). A limitation
of this study is that mass spectra were searched against a
protein database containing only wildtype proteins, however,
so that mutant proteins could not be identified. An alternative
strategy is to generate mutant protein databases using tumor
genome sequencing data, either specific to the patient’s tu-
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mor or using commonly identified variants and search mass
spectra against these (61). This proteogenomic approach has
the potential to reveal tumor-specific proteins, however, sig-
nificant technical challenges remain in controlling the protein
database size and false-discovery rate (62).
Potentially because of this limitation, no entirely tumor-
specific proteins could be identified in this study. Importantly,
however, a group of proteins highly expressed in tumors
relative to surrounding normal tissues was proposed (Fig. 6).
Immunotherapeutic trials are already underway in other can-
cer types with agents directed against several of these includ-
ing EPCAM (63), glycoprotein A33; GPA33 (64, 65), mucin 1,
cell surface associated; MUC1 (66) and melanoma antigen;
MAGE (67) proteins. If the expression of these can be vali-
dated to be specific to EAC cells over surrounding tissues,
there would be a compelling rationale to expand trials to
include patients with EAC and to develop specific imaging
tools to these targets to enhance clinical staging.
These data have been presented, in part, at the Human
Proteome Organisation (HUPO) World Congress in 2012 and
the Association of Upper-GI Surgeons of Great Britain and
Ireland (AUGIS) in 2013 and published in abstract form (British
Journal of Surgery 2013;100(S8):55).
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